Annual CFI
-$131.50 M
-$3.26 M-2.54%
31 December 2023
Summary:
BioCryst Pharmaceuticals annual cash flow from investing activities is currently -$131.50 million, with the most recent change of -$3.26 million (-2.54%) on 31 December 2023. During the last 3 years, it has fallen by -$124.64 million (-1818.00%). BCRX annual CFI is now -268.73% below its all-time high of $77.93 million, reached on 31 December 2019.BCRX Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
$8.49 M
+$10.94 M+446.63%
30 September 2024
Summary:
BioCryst Pharmaceuticals quarterly cash flow from investing activities is currently $8.49 million, with the most recent change of +$10.94 million (+446.63%) on 30 September 2024. Over the past year, it has dropped by -$14.63 million (-63.28%). BCRX quarterly CFI is now -89.01% below its all-time high of $77.22 million, reached on 31 December 2022.BCRX Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
$6.32 M
-$14.63 M-69.82%
30 September 2024
Summary:
BioCryst Pharmaceuticals TTM cash flow from investing activities is currently $6.32 million, with the most recent change of -$14.63 million (-69.82%) on 30 September 2024. Over the past year, it has increased by +$32.13 million (+124.50%). BCRX TTM CFI is now -91.89% below its all-time high of $77.93 million, reached on 31 December 2019.BCRX TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCRX Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -2.5% | -63.3% | +124.5% |
| 3 y3 years | -1818.0% | +9.6% | -86.9% |
| 5 y5 years | -2857.9% | -63.9% | -89.2% |
BCRX Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -932.1% | at low | -89.0% | +107.9% | -86.9% | +102.9% |
| 5 y | 5 years | -268.7% | at low | -89.0% | +107.9% | -91.9% | +102.9% |
| alltime | all time | -268.7% | at low | -89.0% | +107.9% | -91.9% | +102.9% |
BioCryst Pharmaceuticals Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $8.49 M(-446.6%) | $6.32 M(-69.8%) |
| June 2024 | - | -$2.45 M(-108.5%) | $20.95 M(+379.8%) |
| Mar 2024 | - | $28.76 M(-201.0%) | $4.37 M(-103.3%) |
| Dec 2023 | -$131.50 M(+2.5%) | -$28.47 M(-223.2%) | -$131.50 M(+409.5%) |
| Sept 2023 | - | $23.12 M(-221.5%) | -$25.81 M(-78.2%) |
| June 2023 | - | -$19.04 M(-82.2%) | -$118.47 M(-39.8%) |
| Mar 2023 | - | -$107.11 M(-238.7%) | -$196.88 M(+53.5%) |
| Dec 2022 | -$128.24 M(-911.4%) | $77.22 M(-211.0%) | -$128.24 M(-40.8%) |
| Sept 2022 | - | -$69.54 M(-28.6%) | -$216.57 M(+55.5%) |
| June 2022 | - | -$97.44 M(+153.3%) | -$139.28 M(+273.0%) |
| Mar 2022 | - | -$38.47 M(+246.0%) | -$37.34 M(-336.3%) |
| Dec 2021 | $15.80 M(-330.5%) | -$11.12 M(-243.5%) | $15.80 M(-67.3%) |
| Sept 2021 | - | $7.75 M(+72.0%) | $48.34 M(+640.4%) |
| June 2021 | - | $4.50 M(-69.3%) | $6.53 M(-324.6%) |
| Mar 2021 | - | $14.67 M(-31.5%) | -$2.91 M(-57.6%) |
| Dec 2020 | -$6.86 M(-108.8%) | $21.41 M(-162.9%) | -$6.86 M(-42.9%) |
| Sept 2020 | - | -$34.06 M(+590.6%) | -$12.01 M(-126.4%) |
| June 2020 | - | -$4.93 M(-146.0%) | $45.57 M(-37.4%) |
| Mar 2020 | - | $10.72 M(-34.1%) | $72.78 M(-6.6%) |
| Dec 2019 | $77.93 M(+1534.5%) | $16.26 M(-30.8%) | $77.93 M(+33.2%) |
| Sept 2019 | - | $23.51 M(+5.5%) | $58.51 M(+129.7%) |
| June 2019 | - | $22.28 M(+40.3%) | $25.47 M(+439.3%) |
| Mar 2019 | - | $15.88 M(-601.5%) | $4.72 M(-1.0%) |
| Dec 2018 | $4.77 M(-107.4%) | -$3.17 M(-66.8%) | $4.77 M(-109.6%) |
| Sept 2018 | - | -$9.53 M(-721.3%) | -$49.45 M(+30.3%) |
| June 2018 | - | $1.53 M(-90.4%) | -$37.96 M(-39.6%) |
| Mar 2018 | - | $15.93 M(-127.8%) | -$62.85 M(-2.8%) |
| Dec 2017 | -$64.64 M(-377.8%) | -$57.38 M(-3023.3%) | -$64.64 M(+278.4%) |
| Sept 2017 | - | $1.96 M(-108.4%) | -$17.09 M(-688.9%) |
| June 2017 | - | -$23.35 M(-265.2%) | $2.90 M(-91.6%) |
| Mar 2017 | - | $14.13 M(-243.8%) | $34.70 M(+49.1%) |
| Dec 2016 | $23.27 M(-229.3%) | -$9.83 M(-144.8%) | $23.27 M(-22.7%) |
| Sept 2016 | - | $21.95 M(+159.9%) | $30.11 M(-401.8%) |
| June 2016 | - | $8.44 M(+211.9%) | -$9.98 M(-12.1%) |
| Mar 2016 | - | $2.71 M(-190.6%) | -$11.35 M(-37.0%) |
| Dec 2015 | -$18.00 M(-55.0%) | -$2.99 M(-83.5%) | -$18.00 M(-73.6%) |
| Sept 2015 | - | -$18.14 M(-356.5%) | -$68.11 M(+51.0%) |
| June 2015 | - | $7.07 M(-279.1%) | -$45.10 M(+5.1%) |
| Mar 2015 | - | -$3.95 M(-92.6%) | -$42.91 M(+7.3%) |
| Dec 2014 | -$39.98 M(+1053.2%) | -$53.09 M(-1191.2%) | -$39.98 M(-468.6%) |
| Sept 2014 | - | $4.87 M(-47.5%) | $10.85 M(+6205.8%) |
| June 2014 | - | $9.27 M(-1005.8%) | $172.00 K(-102.6%) |
| Mar 2014 | - | -$1.02 M(-54.8%) | -$6.56 M(+89.3%) |
| Dec 2013 | -$3.47 M(-113.9%) | -$2.26 M(-61.1%) | -$3.47 M(-242.0%) |
| Sept 2013 | - | -$5.81 M(-329.4%) | $2.44 M(-87.7%) |
| June 2013 | - | $2.53 M(+22.2%) | $19.93 M(+29.2%) |
| Mar 2013 | - | $2.07 M(-43.2%) | $15.42 M(-38.0%) |
| Dec 2012 | $24.88 M(+119.9%) | $3.65 M(-68.8%) | $24.88 M(+34.2%) |
| Sept 2012 | - | $11.68 M(-690.5%) | $18.55 M(-20.1%) |
| June 2012 | - | -$1.98 M(-117.1%) | $23.21 M(+53.7%) |
| Mar 2012 | - | $11.54 M(-528.7%) | $15.10 M(+33.4%) |
| Dec 2011 | $11.32 M(+5021.3%) | -$2.69 M(-116.5%) | $11.32 M(-48.9%) |
| Sept 2011 | - | $16.34 M(-262.0%) | $22.13 M(+83.6%) |
| June 2011 | - | -$10.09 M(-230.0%) | $12.05 M(-50.6%) |
| Mar 2011 | - | $7.76 M(-4.5%) | $24.39 M(>+9900.0%) |
| Dec 2010 | $221.00 K(-101.7%) | $8.12 M(+29.8%) | $221.00 K(-100.5%) |
| Sept 2010 | - | $6.26 M(+178.6%) | -$40.93 M(+4.5%) |
| June 2010 | - | $2.25 M(-113.7%) | -$39.15 M(+21.4%) |
| Mar 2010 | - | -$16.41 M(-50.3%) | -$32.24 M(+150.0%) |
| Dec 2009 | -$12.89 M | -$33.03 M(-510.8%) | -$12.89 M(-141.5%) |
| Sept 2009 | - | $8.04 M(-12.2%) | $31.03 M(+58.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2009 | - | $9.16 M(+212.3%) | $19.56 M(+44.0%) |
| Mar 2009 | - | $2.93 M(-73.1%) | $13.58 M(+19.2%) |
| Dec 2008 | $11.39 M(-175.8%) | $10.90 M(-417.4%) | $11.39 M(+223.0%) |
| Sept 2008 | - | -$3.44 M(-208.0%) | $3.53 M(-120.9%) |
| June 2008 | - | $3.18 M(+326.4%) | -$16.92 M(-23.7%) |
| Mar 2008 | - | $746.00 K(-75.4%) | -$22.18 M(+47.5%) |
| Dec 2007 | -$15.03 M(+20.4%) | $3.04 M(-112.7%) | -$15.03 M(+127.4%) |
| Sept 2007 | - | -$23.88 M(+1046.3%) | -$6.61 M(-151.5%) |
| June 2007 | - | -$2.08 M(-126.4%) | $12.83 M(+26.6%) |
| Mar 2007 | - | $7.89 M(-31.1%) | $10.13 M(-181.1%) |
| Dec 2006 | -$12.49 M(+8.5%) | $11.46 M(-358.2%) | -$12.49 M(-57.4%) |
| Sept 2006 | - | -$4.44 M(-7.2%) | -$29.32 M(+46.1%) |
| June 2006 | - | -$4.78 M(-67.6%) | -$20.07 M(-9.5%) |
| Mar 2006 | - | -$14.73 M(+174.0%) | -$22.18 M(+92.7%) |
| Dec 2005 | -$11.51 M(+305.9%) | -$5.38 M(-211.6%) | -$11.51 M(+417.3%) |
| Sept 2005 | - | $4.82 M(-169.9%) | -$2.23 M(-66.3%) |
| June 2005 | - | -$6.89 M(+69.7%) | -$6.62 M(-3816.3%) |
| Mar 2005 | - | -$4.06 M(-203.8%) | $178.00 K(-106.3%) |
| Dec 2004 | -$2.84 M(-133.9%) | $3.91 M(+811.9%) | -$2.84 M(-26.0%) |
| Sept 2004 | - | $429.00 K(-524.8%) | -$3.84 M(-12.7%) |
| June 2004 | - | -$101.00 K(-98.6%) | -$4.39 M(-626.9%) |
| Mar 2004 | - | -$7.08 M(-342.9%) | $834.00 K(-90.0%) |
| Dec 2003 | $8.37 M(-18.5%) | $2.91 M(-2358.1%) | $8.37 M(+18.6%) |
| Sept 2003 | - | -$129.00 K(-102.5%) | $7.06 M(-23.6%) |
| June 2003 | - | $5.13 M(+1019.4%) | $9.23 M(+84.3%) |
| Mar 2003 | - | $458.00 K(-71.4%) | $5.01 M(-51.2%) |
| Dec 2002 | $10.26 M(-49.6%) | $1.60 M(-21.8%) | $10.26 M(-9.8%) |
| Sept 2002 | - | $2.05 M(+126.2%) | $11.38 M(-11.2%) |
| June 2002 | - | $905.00 K(-84.2%) | $12.80 M(-18.6%) |
| Mar 2002 | - | $5.71 M(+110.5%) | $15.72 M(-22.9%) |
| Dec 2001 | $20.38 M(+1292.6%) | $2.71 M(-21.9%) | $20.38 M(+7.1%) |
| Sept 2001 | - | $3.48 M(-9.1%) | $19.03 M(+10.6%) |
| June 2001 | - | $3.82 M(-63.2%) | $17.20 M(+23.3%) |
| Mar 2001 | - | $10.37 M(+663.4%) | $13.95 M(+853.0%) |
| Dec 2000 | $1.46 M(-103.1%) | $1.36 M(-17.4%) | $1.46 M(-103.3%) |
| Sept 2000 | - | $1.64 M(+186.4%) | -$44.09 M(-1.2%) |
| June 2000 | - | $574.00 K(-127.2%) | -$44.64 M(-7.4%) |
| Mar 2000 | - | -$2.11 M(-95.2%) | -$48.21 M(+1.1%) |
| Dec 1999 | -$47.70 M(-922.4%) | -$44.20 M(-4118.2%) | -$47.70 M(+622.7%) |
| Sept 1999 | - | $1.10 M(-136.7%) | -$6.60 M(+78.4%) |
| June 1999 | - | -$3.00 M(+87.5%) | -$3.70 M(-254.2%) |
| Mar 1999 | - | -$1.60 M(-48.4%) | $2.40 M(-58.6%) |
| Dec 1998 | $5.80 M(-43.1%) | -$3.10 M(-177.5%) | $5.80 M(-42.0%) |
| Sept 1998 | - | $4.00 M(+29.0%) | $10.00 M(+6.4%) |
| June 1998 | - | $3.10 M(+72.2%) | $9.40 M(+2.2%) |
| Mar 1998 | - | $1.80 M(+63.6%) | $9.20 M(-9.8%) |
| Dec 1997 | $10.20 M(-137.5%) | $1.10 M(-67.6%) | $10.20 M(-169.9%) |
| Sept 1997 | - | $3.40 M(+17.2%) | -$14.60 M(-3.3%) |
| June 1997 | - | $2.90 M(+3.6%) | -$15.10 M(-30.7%) |
| Mar 1997 | - | $2.80 M(-111.8%) | -$21.80 M(-19.9%) |
| Dec 1996 | -$27.20 M(-1107.4%) | -$23.70 M(-917.2%) | -$27.20 M(+209.1%) |
| Sept 1996 | - | $2.90 M(-176.3%) | -$8.80 M(-22.8%) |
| June 1996 | - | -$3.80 M(+46.2%) | -$11.40 M(+418.2%) |
| Mar 1996 | - | -$2.60 M(-50.9%) | -$2.20 M(-181.5%) |
| Dec 1995 | $2.70 M(-131.4%) | -$5.30 M(-1866.7%) | $2.70 M(-64.0%) |
| Sept 1995 | - | $300.00 K(-94.4%) | $7.50 M(-13.8%) |
| June 1995 | - | $5.40 M(+134.8%) | $8.70 M(+480.0%) |
| Mar 1995 | - | $2.30 M(-560.0%) | $1.50 M(-117.4%) |
| Dec 1994 | -$8.60 M | -$500.00 K(-133.3%) | -$8.60 M(+6.2%) |
| Sept 1994 | - | $1.50 M(-183.3%) | -$8.10 M(-15.6%) |
| June 1994 | - | -$1.80 M(-76.9%) | -$9.60 M(+23.1%) |
| Mar 1994 | - | -$7.80 M | -$7.80 M |
FAQ
- What is BioCryst Pharmaceuticals annual cash flow from investing activities?
- What is the all time high annual CFI for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals annual CFI year-on-year change?
- What is BioCryst Pharmaceuticals quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals quarterly CFI year-on-year change?
- What is BioCryst Pharmaceuticals TTM cash flow from investing activities?
- What is the all time high TTM CFI for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals TTM CFI year-on-year change?
What is BioCryst Pharmaceuticals annual cash flow from investing activities?
The current annual CFI of BCRX is -$131.50 M
What is the all time high annual CFI for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high annual cash flow from investing activities is $77.93 M
What is BioCryst Pharmaceuticals annual CFI year-on-year change?
Over the past year, BCRX annual cash flow from investing activities has changed by -$3.26 M (-2.54%)
What is BioCryst Pharmaceuticals quarterly cash flow from investing activities?
The current quarterly CFI of BCRX is $8.49 M
What is the all time high quarterly CFI for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high quarterly cash flow from investing activities is $77.22 M
What is BioCryst Pharmaceuticals quarterly CFI year-on-year change?
Over the past year, BCRX quarterly cash flow from investing activities has changed by -$14.63 M (-63.28%)
What is BioCryst Pharmaceuticals TTM cash flow from investing activities?
The current TTM CFI of BCRX is $6.32 M
What is the all time high TTM CFI for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high TTM cash flow from investing activities is $77.93 M
What is BioCryst Pharmaceuticals TTM CFI year-on-year change?
Over the past year, BCRX TTM cash flow from investing activities has changed by +$32.13 M (+124.50%)